Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Rating) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totalling 378,600 shares, a decline of 41.3% from the June 15th total of 644,700 shares. Based on an average trading volume of 967,600 shares, the short-interest ratio is presently 0.4 days. Approximately 2.5% of the company's shares are sold short.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group cut their price target on shares of Finch Therapeutics Group from $29.00 to $17.00 and set a "buy" rating on the stock in a report on Monday, April 4th.

Institutional Trading of Finch Therapeutics Group

A number of hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC boosted its holdings in shares of Finch Therapeutics Group by 19.4% during the 1st quarter. Renaissance Technologies LLC now owns 45,000 shares of the company's stock valued at $226,000 after buying an additional 7,314 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Finch Therapeutics Group by 2.3% during the 1st quarter. BlackRock Inc. now owns 404,931 shares of the company's stock valued at $2,038,000 after buying an additional 9,149 shares in the last quarter. Qube Research & Technologies Ltd boosted its holdings in shares of Finch Therapeutics Group by 53.6% during the 1st quarter. Qube Research & Technologies Ltd now owns 37,631 shares of the company's stock valued at $189,000 after buying an additional 13,128 shares in the last quarter. Lake Street Advisors Group LLC boosted its holdings in shares of Finch Therapeutics Group by 16.2% during the 4th quarter. Lake Street Advisors Group LLC now owns 739,136 shares of the company's stock valued at $7,369,000 after buying an additional 102,941 shares in the last quarter. Finally, Light Street Capital Management LLC boosted its holdings in shares of Finch Therapeutics Group by 1.8% during the 4th quarter. Light Street Capital Management LLC now owns 811,731 shares of the company's stock valued at $8,093,000 after buying an additional 14,400 shares in the last quarter. Institutional investors own 22.68% of the company's stock.

Finch Therapeutics Group Stock Performance

Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $0.35 million during the quarter. Finch Therapeutics Group had a negative net margin of 448.35% and a negative return on equity of 33.13%. As a group, research analysts predict that Finch Therapeutics Group will post -1.98 EPS for the current year.

Finch Therapeutics Group Company Profile

(Get Rating)

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus.

Further Reading

• Get a free copy of the StockNews.com research report on Finch Therapeutics Group (FNCH)
• MarketBeat: Week in Review 7/11 – 7/15
• Should You Have These Two Banks In Your Portfolio?
• Is Coupang's Stock On The Verge Of A Turnaround?
• Why Shopify Stock Split...And is as Shoppable as Ever
• Verint Systems Stock is a Customer Engagement Play

Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.